UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Québec 001-39335 Not applicable (I.R.S. Employer Identification No.) Registrant's Telephone Number, Including Area Code: (857) 412-7018 Date of Report (Date of earliest event reported): January 9, 2025 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) 7171 Frederick-B ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 675 Massachusetts Avenue, 14th Floor Cambridge, Massachusett ...

Exhibit 99.1 Neogen Announces Preliminary 1 Second-Quarter 2025 Results 1 Results presented in this release are preliminary and unaudited estimates based on information currently available to the Company. Such results could differ from the final amounts the Company reports in its Quarterly Report on Form 10-Q for the fiscal quarter ended November 30, 2024. The Company assumes no obligation, and does not intend, to update these estimates prior to filing its Form 10-Q. 2 Non-GAAP financial measures; see expla ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Date of Report (Date of earliest event reported): January 8, 2025 PASSAGE BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39231 82-2729751 (State or other jurisdiction of incorporation) One Commerce Square 2005 Market Street, 39 Floor Philadelphia, PA 19103 (Address of principal executive offices) (Zip Code) (Commission File Number) (IRS Employer Identification No.) (267) 866-0311 FORM 8-K CURRENT REPORT Pu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2025 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 101 Cambridgepark Drive Cambridge, MA 02140 (Address of princip ...

EXHIBIT 99.1 Tilray Brands Reports Q2 2025 Financial Results Gross Profit Increased by 29% Year-Over-Year, Reaching $61 Million in Q2 with Growth Across All Four Business Segments Achieved 9% Year-Over-Year Growth, Generating Record Q2 Net Revenue of $211 Million, 10% in Constant Currency Beverage Revenue Increase by 36%, International Cannabis by 25%, Wellness Segment by 13% Announces Project 420: A $25 Million Synergy Plan for Tilray Beverage Business Tilray Reaffirms Fiscal Year 2025 Guidance Conference ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2025 Dyne Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39509 36-4883909 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1560 Trapelo Road Waltham, Massachusetts 02451 (Address of Principa ...

| 证券代码：000591 | 证券简称：太阳能 | 公告编号：2025-09 | | --- | --- | --- | | 债券代码：149812 | 债券简称：22太阳 G1 | | | 债券代码：148296 | 债券简称：23太阳 GK02 | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、本期业绩预计情况 1. 业绩预告期间：2024年1月1日至2024年12月31日 | 项 目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司 股东的净利润 | 盈利：120,000 万元–125,000 万元 | 盈利：157,865.60 万元 | | | 比上年同期下降：20.82%–23.99% | | | 归属于上市公司 股东的扣除非经 | 盈利：114,000 万元–119,000 万元 | 盈利：149,541.36 万元 | | 常性损益后的净 | | | | | 比上年同期下降：20.42%–23.77% | | | 利润 | | | | 基本每股收益 | 盈利：0.3067 元/股–0.319 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 ASTRONICS CORPORATION (Exact name of registrant as specified in its charter) New York 0-7087 16-0959303 (State of Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 130 Commerce Way East Aurora, New York 14052 (Address of principa ...

证券代码：300503 证券简称：昊志机电 公告编号：2025-001 3、业绩预告情况表： 广州市昊志机电股份有限公司 2024年度业绩预告 | 项目 | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | | 归属于上市公司 | 盈利：7,000 | 万元 万元–10,200 | 亏损：19,396.90 | 万元 | | 股东的净利润 | | | | | | 扣除非经常性损 | 盈利：4,200 | 万元–6,000 万元 | 亏损：23,880.76 | 万元 | | 益后的净利润 | | | | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 注：上表中"万元"均为人民币万元。 二、与会计师事务所沟通情况 1、业绩预告期间：2024 年 1 月 1 日—2024 年 12 月 31 日 2、预计的业绩：□亏损 √扭亏为盈 □同向上升 □同向下降 2、公司本期资产减值损失和信用减值损失的最终金额将由公司聘请的具备 证券期货从业资格的评估机构及审计机构进行评估和审计后确定，后续公司 ...